Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HY-PHEN vs NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
HY-PHEN is a combination of hydrocodone (a mu-opioid receptor agonist) and acetaminophen (an analgesic and antipyretic). Hydrocodone binds to mu-opioid receptors in the CNS, altering pain perception and emotional response to pain. Acetaminophen inhibits cyclooxygenase (COX) enzymes, particularly in the CNS, reducing prostaglandin synthesis.
Pentazocine is a mixed agonist-antagonist opioid that binds to mu-opioid receptors (partial agonist) and kappa-opioid receptors (agonist), producing analgesia. Naloxone is a pure opioid antagonist that competitively blocks mu, kappa, and delta receptors; when administered orally, naloxone undergoes extensive first-pass metabolism, reducing systemic absorption and primarily blocking the effects of pentazocine if the combination is misused parenterally.
Management of moderate to moderately severe pain,Off-label: Acute pain, postoperative pain, chronic pain (limited use due to acetaminophen toxicity risk)
Moderate to severe pain relief; combinations are used to reduce abuse potential.
1-2 tablets (acetaminophen 500 mg/hydrocodone 5-10 mg) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
Oral: One tablet (naloxone 0.5 mg / pentazocine 50 mg) every 3-4 hours as needed for pain; maximum 12 tablets daily.
2-3 hours (terminal elimination half-life). Clinical context: Short half-life requires frequent dosing (every 4-6 hours) for sustained analgesic effect.
Pentazocine has an elimination half-life of 2-3 hours in healthy adults, which may be prolonged in patients with hepatic impairment. Naloxone has a terminal half-life of 0.5-1.5 hours in adults, with a rapid decline in plasma levels; the short half-life limits its duration of opioid antagonism.
Hydrocodone is metabolized via CYP3A4 to hydromorphone (active) and via CYP2D6 to norhydrocodone. Acetaminophen is primarily metabolized via glucuronidation and sulfation; a minor pathway via CYP2E1 produces a hepatotoxic metabolite (NAPQI) that is normally detoxified by glutathione.
Pentazocine is metabolized primarily by hepatic conjugation (glucuronidation) and oxidation via CYP2C19 and CYP2D6; naloxone is extensively metabolized by the liver, primarily via glucuronidation (UGT2B7).
Renal (primarily as glucuronide conjugates and unchanged drug). Approximately 90-95% eliminated in urine within 24 hours; fecal excretion <5%.
Pentazocine is primarily metabolized in the liver and excreted in urine as conjugates of glucuronide and sulfate, with about 60% of a dose excreted renally within 24 hours as metabolites and unchanged drug (less than 5% unchanged). Naloxone undergoes extensive hepatic metabolism to naloxone-3-glucuronide, which is excreted renally; approximately 50% of a dose is excreted as conjugates in urine within 6 hours.
25-35% bound to plasma proteins (mainly albumin).
Pentazocine: Approximately 35-65% bound to plasma proteins (mainly albumin). Naloxone: Approximately 32-45% bound to plasma proteins (mainly albumin).
0.9-1.5 L/kg. Clinical meaning: Moderate Vd indicates distribution into total body water; does not extensively accumulate in tissues.
Pentazocine: Vd ~2-3 L/kg, indicating extensive tissue distribution. Naloxone: Vd ~2-3 L/kg, also indicating wide distribution.
Oral: 60-90% (first-pass metabolism reduces systemic availability); Rectal: 70-80%; IV/IM: 100%.
Oral pentazocine: 20-30% due to first-pass metabolism. Intramuscular pentazocine: 100%. Subcutaneous pentazocine: 100%. Oral naloxone: <2% due to extensive first-pass metabolism. Intramuscular and subcutaneous naloxone: 100%. Intravenous: 100% for both.
GFR 30-50 m L/min: administer at 75% of usual dose every 6 hours; GFR <30 m L/min: administer at 50% of usual dose every 8 hours. Avoid in severe renal impairment.
GFR 30-50 m L/min: Administer every 6 hours; GFR 10-29 m L/min: Administer every 8-12 hours; GFR <10 m L/min: Administer every 12 hours or consider alternative.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50% and extend interval to every 8 hours; Class C: contraindicated.
Child-Pugh Class A: No adjustment; Child-Pugh Class B: Reduce dose by 50% or extend interval; Child-Pugh Class C: Avoid use.
Not recommended for children under 18 years due to risk of opioid-related adverse effects; alternative analgesics preferred.
Not recommended for children under 12 years. For older children (≥12 years): Pentazocine 50 mg (with naloxone 0.5 mg) orally every 3-4 hours as needed; maximum 6 tablets daily.
Initiate with lowest effective dose (e.g., acetaminophen 500 mg/hydrocodone 5 mg) every 6 hours; monitor for respiratory depression, constipation, and falls; may require dose reduction by 25-50% compared to younger adults.
Initiate with half the usual adult dose (one-half tablet) and titrate carefully due to increased sensitivity and risk of respiratory depression.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion of acetaminophen (especially in children) can cause hepatotoxicity; neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risks from concomitant use with benzodiazepines or other CNS depressants (additive respiratory depression).
Risk of respiratory depression, particularly in elderly, cachectic, or debilitated patients; risk of addiction, abuse, and misuse; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risk of life-threatening respiratory depression when used with benzodiazepines or other CNS depressants.
Hepatotoxicity due to acetaminophen (dose-dependent); respiratory depression (especially in elderly, debilitated, or COPD); opioid-induced hyperalgesia; adrenal insufficiency; severe hypotension; seizures; serotonin syndrome with serotonergic drugs; urinary retention; bile duct spasm; use in patients with head injury or increased intracranial pressure (risk of masking neurological signs); neonatal withdrawal syndrome.
Respiratory depression; hypotension; increased intracranial pressure; seizure risk (pentazocine); opioid-induced hyperalgesia; adrenal insufficiency; severe hypotension; interaction with MAOIs; risk of dependence and withdrawal; gastrointestinal obstruction; impaired renal or hepatic function; head injury.
Significant respiratory depression; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction (e.g., paralytic ileus); severe hepatic impairment; hypersensitivity to hydrocodone, acetaminophen, or any component; use of MAO inhibitors within 14 days (hypertensive crisis).
Hypersensitivity to pentazocine or naloxone; significant respiratory depression; acute or severe bronchial asthma; GI obstruction; known or suspected paralytic ileus; patients receiving MAOIs or within 14 days.
Avoid alcohol consumption due to increased risk of hepatotoxicity and CNS depression. Grapefruit juice may inhibit CYP2D6 metabolism of hydrocodone, potentially altering analgesic effect; avoid concurrent use. High-fat meals may increase absorption of hydrocodone; take consistently with or without food.
No specific food interactions are reported for this combination. However, grapefruit juice may theoretically affect metabolism via CYP3A4 (pentazocine is metabolized by CYP3A4), but clinical significance is unknown. Advise patients to maintain a consistent diet.
Pregnancy Category C. First trimester: No well-controlled studies; potential for fetal harm based on animal studies (cleft palate, skeletal anomalies). Second and third trimesters: Prolonged use may cause neonatal withdrawal syndrome (irritability, hypertonia, respiratory depression) if used near term. Avoid use in pregnancy unless benefit outweighs risk.
Pentazocine crosses the placenta; naloxone has limited placental transfer. No well-controlled human studies. First trimester: Risk cannot be excluded; avoid if possible. Second/Third trimester: Chronic use may cause fetal dependence; neonatal withdrawal syndrome reported. High doses near term may cause neonatal respiratory depression.
HY-PHEN (hydrocodone/acetaminophen) is excreted into breast milk in low concentrations. M/P ratio for hydrocodone is approximately 2.0, for acetaminophen ~1.0. Use caution; monitor infant for sedation, respiratory depression, and poor feeding. Consider risk of neonatal withdrawal if maternal use is chronic.
Pentazocine is excreted in breast milk in small amounts (estimated relative infant dose <3%). Naloxone is poorly bioavailable orally. Generally considered compatible with breastfeeding; monitor infant for sedation or poor feeding. M/P ratio for pentazocine is approximately 1.0.
No specific dose adjustments established for pregnancy. Increased plasma volume and enhanced hepatic metabolism in pregnancy may reduce drug concentrations, potentially requiring higher doses to achieve analgesic effect. However, avoid high doses due to risk of acetaminophen hepatotoxicity and fetal opioid exposure. Use lowest effective dose for shortest duration.
No established dose adjustments for pregnancy; however, pharmacokinetic changes (increased volume of distribution, enhanced clearance) may require higher or more frequent doses of pentazocine for adequate analgesia. Use lowest effective dose and shortest duration.
HY-PHEN is a combination of hydrocodone and acetaminophen. Monitor for acetaminophen hepatotoxicity; maximum daily acetaminophen dose should not exceed 4 g from all sources. Hydrocodone is a prodrug metabolized by CYP2D6 to hydromorphone; poor metabolizers may have reduced analgesia while ultra-rapid metabolizers risk toxicity. Avoid concurrent use with other CNS depressants including alcohol due to additive respiratory depression. Taper dose when discontinuing after prolonged use to prevent withdrawal.
Naloxone in this fixed-dose combination is included to deter opioid abuse by reversing euphoria. The pentazocine component is a mixed agonist-antagonist opioid; naloxone has poor oral bioavailability but becomes active parenterally, precipitating withdrawal in opioid-dependent individuals. Use with caution in patients with impaired renal or hepatic function. Monitor for respiratory depression, especially in opioid-naive patients, as pentazocine alone can cause respiratory depression.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not take other products containing acetaminophen (e.g., Tylenol, cold medicines) while using this medication to avoid liver damage.,Avoid alcohol completely while taking this drug; it increases the risk of liver damage and severe drowsiness.,Do not drive or operate heavy machinery until you know how this medication affects you; it may cause dizziness or drowsiness.,Store securely away from children and others; misuse can cause addiction, overdose, or death.,Do not stop taking suddenly after long-term use; your doctor will help you taper off to prevent withdrawal symptoms.
Take exactly as prescribed; do not crush or inject tablets, as injected naloxone can cause severe withdrawal in opioid-dependent individuals.,This medication contains naloxone to discourage misuse; injection will cause withdrawal symptoms.,Report any signs of withdrawal (e.g., nausea, vomiting, sweating, agitation) or breathing difficulty.,Avoid alcohol and other central nervous system depressants as they increase risk of respiratory depression.,Do not use with other opioids unless directed, as effects are unpredictable.,Keep out of reach of children; accidental ingestion may cause severe respiratory depression.
No interactions on record
"Cobicistat is a potent CYP3A4 inhibitor used to boost the pharmacokinetics of antiretroviral agents like atazanavir and darunavir. Naloxone primarily undergoes glucuronidation via UGT1A6 and UGT2B7, with minor CYP3A4 metabolism. Concomitant use with Cobicistat may modestly increase naloxone exposure due to CYP3A4 inhibition, but this is unlikely to be clinically significant given naloxone's wide therapeutic index and short half-life."
"Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), is primarily metabolized by cytochrome P450 (CYP) 1A2 and 2D6. Naloxone, an opioid antagonist, is reported to inhibit CYP1A2, potentially decreasing the clearance of fluvoxamine. This interaction may lead to increased fluvoxamine plasma concentrations, elevating the risk of serotonin syndrome, QT prolongation, and other dose-dependent adverse effects, especially in patients receiving high doses or those with hepatic impairment."
"Naloxone, an opioid receptor antagonist, may inhibit the cytochrome P450 isoenzyme CYP3A4, which is responsible for the metabolism of ivacaftor. Concomitant administration can lead to reduced clearance of ivacaftor, resulting in elevated serum concentrations. This increase may potentiate the therapeutic effects and adverse reactions of ivacaftor, such as hepatotoxicity and QT prolongation."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HY-PHEN vs NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, answered by our medical review team.
HY-PHEN is a Opioid Antitussive Combination that works by HY-PHEN is a combination of hydrocodone (a mu-opioid receptor agonist) and acetaminophen (an analgesic and antipyretic). Hydrocodone binds to mu-opioid receptors in the CNS, altering pain perception and emotional response to pain. Acetaminophen inhibits cyclooxygenase (COX) enzymes, particularly in the CNS, reducing prostaglandin synthesis.. NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE is a Opioid Agonist-Antagonist that works by Pentazocine is a mixed agonist-antagonist opioid that binds to mu-opioid receptors (partial agonist) and kappa-opioid receptors (agonist), producing analgesia. Naloxone is a pure opioid antagonist that competitively blocks mu, kappa, and delta receptors; when administered orally, naloxone undergoes extensive first-pass metabolism, reducing systemic absorption and primarily blocking the effects of pentazocine if the combination is misused parenterally.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HY-PHEN and NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HY-PHEN is: 1-2 tablets (acetaminophen 500 mg/hydrocodone 5-10 mg) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.. The standard adult dose of NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE is: Oral: One tablet (naloxone 0.5 mg / pentazocine 50 mg) every 3-4 hours as needed for pain; maximum 12 tablets daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HY-PHEN and NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HY-PHEN is classified as Category C. Pregnancy Category C. First trimester: No well-controlled studies; potential for fetal harm based on animal studies (cleft palate, skeletal anomalies). Second and third trimesters:. NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE is classified as Category A/B. Pentazocine crosses the placenta; naloxone has limited placental transfer. No well-controlled human studies. First trimester: Risk cannot be excluded; avoid if possible. Second/Thi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.